Literature DB >> 12357012

Osteoporosis.

S P Tuck1, R M Francis.   

Abstract

Osteoporosis is characterised by low bone mass and microarchitectural deterioration of bone tissue, leading to enhanced bone fragility and consequent increase in fracture risk. It is a common condition affecting one in three women and one in 12 men, resulting in substantial morbidity, excess mortality, and health and social services expenditure. It is therefore important to develop strategies to prevent and treat osteoporosis in both men and women. This paper reviews the pathogenesis of primary and secondary osteoporosis, as well as diagnosis, investigation, and management. This should include lifestyle changes to reduce bone loss and decrease the risk of falls, the identification and treatment of secondary causes of bone loss, and specific treatment for osteoporosis. Hormone replacement therapy, raloxifene, bisphosphonates, calcium and vitamin D, calcitonin, and parathyroid hormone have all been shown to improve bone density and decrease the risk of fracture in specific situations. It is important that treatment is tailored to the individual patient, to ensure compliance and optimise the potential benefits.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12357012      PMCID: PMC1742482          DOI: 10.1136/pmj.78.923.526

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  70 in total

1.  Novel insights into the pathogenesis of osteoporosis: the role of intrauterine programming.

Authors:  C Cooper; K Walker-Bone; N Arden; E Dennison
Journal:  Rheumatology (Oxford)       Date:  2000-12       Impact factor: 7.580

2.  Risk factors for falls as a cause of hip fracture in women. The Northeast Hip Fracture Study Group.

Authors:  J A Grisso; J L Kelsey; B L Strom; G Y Chiu; G Maislin; L A O'Brien; S Hoffman; F Kaplan
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

Review 3.  Sex hormones and osteoporosis in men.

Authors:  F H Anderson; R M Francis; P L Selby; C Cooper
Journal:  Calcif Tissue Int       Date:  1998-03       Impact factor: 4.333

4.  Hyperthyroidism and calcium metabolism.

Authors:  D A Smith; S A Fraser; G M Wilson
Journal:  Clin Endocrinol Metab       Date:  1973-07

5.  Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.

Authors:  G P Lyritis; I Paspati; T Karachalios; D Ioakimidis; G Skarantavos; P G Lyritis
Journal:  Acta Orthop Scand Suppl       Date:  1997-10

6.  Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study.

Authors:  J D Ringe; H Faber; A Dorst
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

7.  Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption.

Authors:  F H Anderson; R M Francis; R T Peaston; H J Wastell
Journal:  J Bone Miner Res       Date:  1997-03       Impact factor: 6.741

8.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors:  S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal:  Am J Med       Date:  1993-12       Impact factor: 4.965

9.  Progressive loss of bone in the femoral neck in elderly people: longitudinal findings from the Dubbo osteoporosis epidemiology study.

Authors:  G Jones; T Nguyen; P Sambrook; P J Kelly; J A Eisman
Journal:  BMJ       Date:  1994-09-17

10.  A multifactorial intervention to reduce the risk of falling among elderly people living in the community.

Authors:  M E Tinetti; D I Baker; G McAvay; E B Claus; P Garrett; M Gottschalk; M L Koch; K Trainor; R I Horwitz
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

View more
  7 in total

1.  Bisphosphonate treatment in ochronotic osteoporotic patients.

Authors:  Giuseppe Aliberti; Isabella Pulignano; Daniela Pisani; Massimiliano Rocchietti March; Flavia Del Porto; Maria Proietta
Journal:  Clin Rheumatol       Date:  2006-08-19       Impact factor: 2.980

2.  Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.

Authors:  Christos Markopoulos; Evagelos Tzoracoleftherakis; Athanassios Polychronis; Basileios Venizelos; Urania Dafni; Grigorios Xepapadakis; John Papadiamantis; Vasilios Zobolas; John Misitzis; Kyriakos Kalogerakos; Angeliki Sarantopoulou; Nikolaos Siasos; Dimitrios Koukouras; Zoh Antonopoulou; Spyros Lazarou; Helen Gogas
Journal:  Breast Cancer Res       Date:  2010-04-16       Impact factor: 6.466

3.  Poor histological healing of a femoral fracture following 12 months of oestrogen deficiency in rats.

Authors:  R A Oliver; Y Yu; G Yee; A K Low; A D Diwan; W R Walsh
Journal:  Osteoporos Int       Date:  2013-04-06       Impact factor: 4.507

4.  Expressions and clinical significance of serum bone Gla-protein, bone alkaline phosphatase and C-terminal telopeptide of type I collagen in bone metabolism of patients with osteoporosis.

Authors:  Dongfeng Zhao; Junsheng Wang; Yining Liu; Xinwei Liu
Journal:  Pak J Med Sci       Date:  2015 Jan-Feb       Impact factor: 1.088

5.  Gut microbiota is associated with bone mineral density : an observational and genome-wide environmental interaction analysis in the UK Biobank cohort.

Authors:  Bolun Cheng; Yan Wen; Xuena Yang; Shiqiang Cheng; Li Liu; Xiaomeng Chu; Jing Ye; Chujun Liang; Yao Yao; Yumeng Jia; Feng Zhang
Journal:  Bone Joint Res       Date:  2021-11       Impact factor: 5.853

6.  Falls in older adults with cancer: an updated systematic review of prevalence, injurious falls, and impact on cancer treatment.

Authors:  T M Wildes; S Alibhai; S Sattar; K Haase; S Kuster; M Puts; S Spoelstra; C Bradley
Journal:  Support Care Cancer       Date:  2020-07-16       Impact factor: 3.603

Review 7.  The clinical utility of bone marker measurements in osteoporosis.

Authors:  Gillian Wheater; Mohsen Elshahaly; Stephen P Tuck; Harish K Datta; Jacob M van Laar
Journal:  J Transl Med       Date:  2013-08-29       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.